Home Health Agency Valuation in 2026: What It’s Worth

As of June 2026, the question on most owners’ minds is no longer “should I sell?” but “what is my agency actually worth now?” The answer changed on November 28, 2025, when CMS finalized the Calendar Year 2026 Home Health Prospective Payment System rule a net 1.3% payment decrease, roughly $220 million out of the sector. That is far milder than the 6.4% cut CMS originally proposed, but it landed alongside a quieter shift that matters more for your valuation: buyers have tightened their tolerance for EBITDA add-backs from about 20% down to 12–15%. A home health agency valuation in 2026 is built on durable, provable earnings not the adjusted numbers that cleared diligence two years ago.

This is the calm reality of a reset market. Capital is still available, strategic and private-equity buyers are still active, and the fourth quarter of 2025 recorded 16 hospice transactions the strongest quarter in four years. What has changed is discipline, and discipline rewards owners who prepare. Below is how home health agencies are valued today, what moves the multiple, how the latest regulatory and market shifts factor in, and how to find out what yours is actually worth before you make any decision.

How much is a home health agency worth in 2026?

As of June 2026, most lower-middle-market home health agencies trade between 6.0x and 8.0x EBITDA, or roughly 3.5x to 4.5x SDE for smaller, owner-operated agencies. Hospice assets command more …typically 9.0x to 12.5x EBITDA and private-duty nursing tends to land between 7.0x and 10.0x. These are ranges, not promises: where your agency falls depends on payer mix, geographic footprint, staff retention, and the strength of your referral relationships.

Segment	Typical 2026 multiple	Primary value drivers
Home health (skilled)	6.0x–8.0x EBITDA (3.5x–4.5x SDE)	Medicare certification, episodic margin, clinical outcomes
Hospice	9.0x–12.5x EBITDA	Average length of stay (ALOS), census stability
Private-duty nursing	7.0x–10.0x EBITDA	Utilization rates, credentialing speed
Non-medical home care	4.0x–6.0x EBITDA	Caregiver retention, private-pay share
Scaled regional platform	3–5 turns above add-on multiples	Multi-state footprint, payer diversification, clean compliance

What is the difference between SDE and EBITDA in a home health valuation?

SDE (Seller’s Discretionary Earnings) measures what a single owner-operator takes out of the business, while EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) measures what the business earns independently of any one person. The transition from an SDE-based valuation to an EBITDA-based one is triggered by clinical autonomy…your agency’s proven ability to run audits, manage patient care, and grow without you in every room. Buyers pay higher multiples on EBITDA precisely because it survives your departure.

This is where add-backs matter. An add-back is an expense you argue a buyer won’t inherit an above-market owner salary, a personal vehicle, a one-time legal bill. In 2026, buyers accept fewer of them. Where adjusted EBITDA once carried roughly 20% in add-backs, disciplined buyers now hold that closer to 12–15%. The practical effect: two agencies with identical tax returns can be worth very different amounts depending on how defensible their adjusted earnings are.

How did the 2026 CMS final rule change home health agency values?

The CY 2026 Home Health Final Rule reduced aggregate Medicare home health payments by 1.3% a far smaller cut than the 6.4% CMS proposed in mid-2025, but a reminder that reimbursement risk is now a permanent line in every buyer’s model. CMS finalized a permanent adjustment of -1.023% and a one-year temporary adjustment of -3.0%, netting to roughly $220 million out of the system as of January 2026.

For valuation, the number itself is less important than what it signals. Buyers underwrite reimbursement headwinds far more heavily than they did in the early 2020s. An agency with a diversified payer base Medicare, Medicaid, Veterans Administration, and commercial absorbs a rate adjustment that would meaningfully dent a single-payer agency. Payer mix is consistently cited as the single largest driver of an agency’s multiple, and the 2026 rule is the clearest illustration of why.

The long-term demand picture explains why buyers keep paying despite the rate pressure. The home care market is projected to reach roughly $659.5 billion by the end of 2026 and to climb toward $1.79 trillion by 2036 at about a 10.5% compound annual growth rate, driven by the aging “Silver Tsunami” and the steady migration of care out of institutional settings. At the same time, Medicare Advantage penetration is reshaping authorization and margin dynamics, which is part of why CMS itself cited MA growth when it softened the 2026 permanent adjustment. The result is a market with durable demand and disciplined pricing strong tailwinds for prepared agencies, and real headwinds for those carrying concentrated payer risk.

What drives a home health agency’s valuation multiple?

The multiple a buyer applies is a measure of risk: the more durable and transferable your earnings, the higher the number. As of June 2026, these are the levers that move it most, in both directions.

Driver	Effect on multiple	Why buyers care
Payer diversification	Raises	Reduces exposure to any single rate change (e.g., the 2026 cut)
CMS star rating 4.5+	Raises	Quality scores directly secure future revenue
Caregiver retention above benchmark	Raises	Lowers transition risk and rehiring cost
EBITDA margin 10%–30%	Raises	Signals an efficient, scalable operation
Owner-dependent referrals	Lowers	Earnings may leave when the owner does
Failed surveys or billing audits	Lowers	Triggers steep discounts or a walked deal

Buyers don’t pay for hype. They pay for proof clean books, dependable hours, and a team that runs without you. Most of these levers can be improved in the 6 to 12 months before a sale, which is exactly why an early valuation is worth more than a last-minute one.

How do I calculate my home health agency’s value?

You estimate a home health agency’s value by normalizing earnings, applying a market multiple for your segment, and then adjusting for the risk factors a buyer will scrutinize in diligence. Here is the same sequence an M&A advisor walks through.

1. Start with trailing-twelve-month revenue and net income from your most recent financials, not last year’s tax return.
2. Rebuild EBITDA by adding back interest, taxes, depreciation, and amortization to net income.
3. Apply defensible add-backs only above-market owner compensation, one-time costs, true non-operating expenses. Hold the total near 12–15% to match 2026 buyer expectations.
4. Select your segment multiple from the table above (for skilled home health, 6.0x–8.0x EBITDA).
5. Adjust for payer mix and concentration discount for heavy single-payer reliance, credit for diversification.
6. Adjust for quality and retention a 4.5+ star rating and below-benchmark turnover push you toward the top of the range.
7. Subtract owner-dependency risk if referrals run through your personal network, expect a discount or an earnout.
8. Validate against live demand a calculator gives a range; an advisor with active buyers tells you what the market will actually pay.

Should I get a home health agency valuation now or wait?

Get the valuation now, even if you don’t plan to sell for years. A valuation is a diagnostic, not a commitment.. it shows you which levers are costing you multiple turns while you still have time to fix them. Most owners come to us 6 to 9 months later than they should, after the window to improve payer mix or document referral relationships has narrowed.

The 2026 backdrop reinforces the point. Multiples have softened at the small end and held at the platform end; the middle is where preparation pays for itself. Knowing your number today lets you decide from a position of information rather than urgency whether that means selling into current buyer demand or spending a year making your agency worth more first.

Timing also interacts with deal mechanics that are easy to overlook. The 36-month Medicare rule can restrict a change of majority ownership within 36 months of enrollment or your last ownership change, which shapes both when you can transact and how a buyer structures the deal. Earnouts, transition agreements, and re-enrollment requirements all move faster and cost less when they are planned for rather than discovered mid-process. A valuation conversation surfaces these constraints early, so the timeline you choose is the one the regulations actually allow not the one you assumed. For owners weighing a near-term decision, that clarity is often worth more than the headline number itself.

What do buyers look for in a home health agency in 2026?

In 2026, buyers look for a “platform-ready” agency a resilient operation that can absorb regulatory headwinds and run without the founder, not simply a stream of cash flow. The post-pandemic “growth at all costs” mindset is gone, replaced by a disciplined market focused on sustainable margins, clinical compliance, and geographic density. That shift shows up directly in diligence, where a clean record is now a prerequisite rather than a bonus.

Concretely, a buyer’s diligence team will test a handful of things before they ever confirm a multiple. They will examine your payer mix and any single-payer concentration, because that determines how exposed you are to a rate change like the 2026 cut. They will review survey history and billing audits, since any failed state survey or Medicare audit triggers aggressive discounting or a walked deal. They will measure caregiver turnover against the industry benchmark, because a tenured workforce lowers transition risk. And they will map your referral relationships to see whether they belong to the agency or to you personally owner-dependent referrals are one of the most common reasons a strong-looking agency is discounted at the letter of intent.

None of this is about presenting a perfect business. It is about presenting a provable one. The agencies that command the top of the range are not always the largest; they are the ones whose numbers survive scrutiny because the operator did the documentation work before the process started.

How can I increase my home health agency’s value before a sale?

You increase value by improving the drivers that move the multiple payer diversification, clinical quality, caregiver retention, and reduced owner dependency in the 6 to 12 months before you go to market. A single turn of multiple on a $1.5 million EBITDA agency is $1.5 million in enterprise value, which is why the preparation window is where most of the money is actually made or lost.

• Diversify your payers. Shifting even a portion of revenue away from a single Medicaid waiver or a single MA plan reduces the discount a buyer applies for concentration risk.
• Protect your star rating. A CMS rating of 4.5+ functions as a direct financial multiplier; quality scores secure future revenue in the buyer’s model.
• Stabilize your workforce. Documented retention below the industry turnover benchmark removes a major source of transition risk and rehiring cost.
• Transfer your referral relationships. Move referral sources from your personal network onto the agency’s books, with named relationships and contracts, so the earnings clearly stay after you leave.
• Clean up the financials. Tighten add-backs to a defensible 12–15%, reconcile your books monthly, and resolve any open survey or billing items before diligence begins.

As of June 2026, this is the difference between a valuation that confirms today’s number and one that shows you a higher number you can still reach. An advisor who sees these patterns across many transactions can tell you which one or two levers will move your multiple the most, so you spend the preparation year on what actually pays.

Frequently asked questions about home health agency valuation

What multiple do home health agencies sell for in 2026?

Most home health agencies sell for 6.0x to 8.0x EBITDA in 2026, with smaller owner-operated agencies valued at 3.5x to 4.5x SDE. The exact multiple depends on payer mix, margin, clinical quality, and how dependent the business is on the owner.

Is owning a home health care business profitable?

Yes well-run home health agencies commonly operate at 10% to 30% EBITDA margins, and Medicare-certified agencies with diversified payers and strong retention sit at the high end. Profitability is also what underpins enterprise value, since buyers pay multiples of sustainable earnings.

How does the 2026 CMS payment cut affect my agency’s value?

The CY 2026 final rule lowered Medicare home health payments by a net 1.3%, which buyers fold into their reimbursement-risk modeling. Agencies with diversified payer bases are far less affected than single-payer agencies, so the rule tends to widen the valuation gap between the two.

What is the 36-month Medicare rule?

The 36-month rule generally restricts the change of majority ownership of a Medicare-certified home health agency within 36 months of initial enrollment or the last change of ownership, requiring the buyer to re-enroll rather than assume the existing certification. It can affect deal structure and timing, so confirm how it applies to your agency with qualified counsel before going to market.

How long does it take to sell a home health agency?

A confidential, well-prepared process typically runs 6 to 9 months from valuation to close, depending on payer mix, diligence complexity, and the 36-month rule. Starting with a valuation 6 to 12 months earlier gives you time to improve the drivers that raise your multiple.

Will a valuation obligate me to sell?

No. A valuation is confidential and carries no obligation. It is a planning tool that tells you what your agency is worth today and what would make it worth more, so any future decision is yours to make on your timeline.

Do hospice and private-duty lines change my home health valuation?

Yes. Blended agencies are valued by segment, and hospice census (9.0x–12.5x EBITDA) or private-duty nursing (7.0x–10.0x) can lift a blended multiple above a home-health-only business. Buyers value the diversification and the higher-margin service lines.

About the author

Jason Atty is the founder of Vallexa Advisors, a healthcare-only M&A advisory firm specializing in home health, hospice, and home care transactions. Vallexa works on a 100% success-based fee, runs a confidentiality-first process behind NDA-gated buyer disclosure, and maintains a nationwide buyer network. The firm helps owners understand value, prepare intelligently, and run a confidential sale process that attracts qualified buyers across the home health, hospice, and home care landscape.

Educational only. Not legal, financial, or tax advice. Healthcare M&A outcomes depend on specific facts, payer mix, market conditions, and regulatory context. Speak with qualified counsel before acting on anything in this document.

Estimated reading time: 12 minutes

Hospice Valuation: How to Accurately Value and Maximize Worth of a Hospice Business

How to Value and Sell a Home Care Business in 2026